MedTrace Logo

Non-invasive Liquid Biopsy Analysis of Epigenomics Signatures in Multiple Cancer Types

NCT03869814 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 20000

Last updated 2026-05-15

No results posted yet for this study

Summary

ClearNote Health is developing a test from whole blood for the early detection of multiple cancers. The goal of this study is to employ genomics, epigenomics and proteomics methodology for the detection of cancer signal in the blood of subjects with solid tumors.

Conditions

  • Diagnosis of Cancer of Various Organs

Interventions

OTHER

Blood Draw

Blood Draw

Sponsors & Collaborators

  • ClearNote Health

    lead INDUSTRY

Principal Investigators

  • Samuel Levy, Ph.D. · ClearNote Health, Inc.

Eligibility

Min Age
21 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-04-05
Primary Completion
2029-06-13
Completion
2029-09-13

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03869814 on ClinicalTrials.gov